Background:
- Uveitis is an eye inflammation that can cause vision loss. It is treated with eye drops,
drugs and sometimes surgery. In some people, treatment may not prevent vision loss. A type of
white blood cells called T-cells often have a role in causing uveitis. In some cases of
uveitis, T-cells attack the eye and cause inflammation. A drug called ustekinumab reduces
inflammation from these T-cells. Researchers want to see if ustekinumab can be used to treat
uveitis.
Objectives:
- To see if ustekinumab can be used to treat uveitis.
Eligibility:
- Individuals at least 18 years of age who have active uveitis that needs treatment.
Design:
- Participants will be screened with a physical exam, eye exam, and medical history. Blood
and urine samples will be taken.
- Participants will have at least eight clinic visits during the 64-week study period.
After the first visit, visits will occur at 2, 4, and 8 weeks, and then every 12 weeks.
- Participants will have a ustekinumab injection at the first study visit. They will have
additional doses at the second and third visits, and then every 12 weeks until 1 year
after the first dose (Week 52).
- Treatment will be monitored with frequent blood tests and eye exams. Other standard
treatments for uveitis may be given as needed.
- There will be a final study visit 3 months after the last injection.